ReNeuron Group plc announced that the first patient has been treated in the US Phase IIb clinical study of the Company's CTX cell therapy candidate for stroke disability. The study, designated PISCES III, is a randomised, placebo-controlled clinical trial involving 110 patients across 40 clinical trial sites in the US. Patients with stable post-stroke disability are entered into the study 6 to 12 months after their stroke and are randomised to receive either the CTX therapy or placebo treatment. The primary end-point of the study is a comparison of the proportion of patients in the treated and placebo arms showing a clinically significant improvement on the Modified Rankin Scale, a measure of disability and dependence, at 6 months post-treatment compared with baseline. Top-line results from the study are expected in early 2020.